Trials / Completed
CompletedNCT00127270
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
Using Behavioral Therapy in Combination With Drug-Darifenacin for Symptoms of Overactive Bladder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 395 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darifenacin | Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily |
| DRUG | Darifenacin | Darifenacin tablets 7,5 mg or 15 mg once daily |
| BEHAVIORAL | Behavioral therapy | Behavioral Modification Programme for symptoms of overactive bladder |
Timeline
- Start date
- 2005-05-01
- Completion
- 2006-02-01
- First posted
- 2005-08-05
- Last updated
- 2008-01-24
Locations
67 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00127270. Inclusion in this directory is not an endorsement.